Philips Unveils New Contrast-Enhanced Ultrasound Application for EPIQ Elite Device
The Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound application reportedly leverages micro-bubble contrast media to provide enhanced spatial resolution for imaging of malignant lesions.
Providing an alternative to the use of IV iodinated contrast media for assessing blood flow to and from malignant lesions, Philips has launched the Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound (CEUS) application, which was recently showcased at the International Bubble Conference in Chicago.
Recognizing that iodinated contrast media can lead to tolerability issues for some patients, Philips noted the new CEUS application, available on the Philips EPIQ Elite ultrasound device, utilizes micro-bubble contrast media derived from an inert gas excreted during breathing. The technology offers significantly improved spatial resolution, according to Philips.
Dirk-André Clevert, M.D, said the microvascular imaging capabilities of the new CEUS application elevate clinician assessment of lesions.
“Philips’ microvascular imaging allows us to visualize the pattern of contrast media flow into a lesion, and also shows how it changes over time, which gives us greater diagnostic confidence in assessing indeterminate lesions,” said Dr. Clevert, a professor of radiology at Ludwig-Maximilians-Universität (LMU) in Munich, Germany.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
